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ABSTRACT 
Singapore is a small country, but it is ideally and centrally located to conveniently serve not only its population but 
also patients from the surrounding regions. It’s economy is sufficiently strong to maintain highly sophisticated and 
expensive equipment to manage a high level of healthcare, including oncology services. 
Cancer incidences in Singapore are on an upward trend based on the report of the Singapore Cancer Registry for the 
period of 2001-2005. Cancer is the number one cause of death in Singapore. The three most common cancers for males 
in Singapore, in decreasing occurrences, are colorectal, lung, and prostate. For females, the three most common cancers 
are breast, colorectal, lung cancers. Technological advances and advances in anti-cancer drugs have transformed cancer 
management leading to improved outcomes worldwide and in Singapore as well. The epidemiology and management of 
these common cancers in Singapore are presented. While Singapore presently has five radiotherapy centres (3 public, 2 
private) to service its population of 4.5 million and regional needs, the government has plans to expand its radiotherapy 
services to accommodate the aging population and the rising expectations of increasingly affluent cancer patients 
seeking advanced cancer care. The current and future initiatives spearheaded by Singapore to achieve excellence in this 
aspect are discussed. © 2008 Biomedical Imaging and Intervention Journal. All rights reserved. 
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EPIDEMIOLOGY 
Cancer, being the most common cause of death in 
Singapore, accounts for 30% of all deaths annually. 
Epidemiological data is continuously being collected at 
the Singapore Cancer Registry, and data is obtained via 
notifications by the physicians, pathology records, 
hospital records and death certificates [1]. Table 1 shows 
the number of incident cancers by year of diagnosis from 
2001 to 2005. In general, there was an upward trend in 
the number of incident cancers by year of diagnosis. 
Table 2 shows the number of incident cancer by gender 
in the same time period. Crude incidence rates for total 
male and female cancer patients in the same time period 
were 235.7 and 248.5 per 100,000 Singapore resident 
population respectively. 
Tables 3 and 4 show the top ten most frequent 
cancers in males and females for the period 2001-2005. 
Although colorectal and breast carcinoma were the most 
common carcinomas respectively in males and females, 
lung, colorectal and liver cancers were the top 3 causes 
of cancer mortality in males, while breast, lung and 
colorectal cancers were the top 3 causes of cancer 
mortality in females. 
In comparison with Western countries, Singapore 
has higher incidence rates for cancers of the nose, 
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Table 1  Number of incident cancers by year of diagnosis, 2001-2005. 
Year of diagnosis  2001 2002 2003 2004 2005 2001-2005 




Table 2  Incidence of cancer by gender, 2001-2005      
Gender   Number  %  CR*  ASR** 
Male 20,532 48.5  235.7  226.5 
Female 21,814  51.5  248.5  201.9 
* CR Crude rate per 100,000 per year 





Table 3  Ten most frequent cancers in males, 2001-2005 
Rank Site  No.  %  CR* ASR** 
1 Colo-rectum  3665  17.9  42.1  40.4 
2 Lung  3657  17.8  42.0  41.1 
3  Prostate  1773  8.6 20.4 20.7 
4  Liver  1660  8.1 19.1 18.4 
5  Stomach  1366  6.7 15.7 15.2 
6  Nasopharynx  1163  5.7 13.4 10.5 
7  Skin (incl. Melanoma)  908  4.4  10.4  10.0 
8 Lymphoma  859  4.2  9.9  9.4 
9 Bladder  647  3.2  7.4  7.2 
10 Leukemia  603  2.9  6.9  7.2 
* CR Crude rate per 100,000 per year 





Table 4  Ten most frequent cancers in females, 2001-2005 
Rank Site  No.  %  CR* ASR** 
1 Breast  6405  29.4  73.0  57.4 
2 Colo-rectum  3142  14.4  35.8  29.2 
3 Lung  1761  8.1  20.1  16.2 
4 Ovary  1251  5.7  14.2  11.8 
5 Corpus  Uteri  1176  5.4  13.4  10.9 
6 Cervix  Uteri  1001  4.6  11.4  9.1 
7 Stomach  877  4.0  10.0  7.9 
8  Skin (incl. Melanoma)  798  3.7  9.1  7.2 
9 Thyroid  647  3.0  7.4  6.1 
10 Lymphoma  619  2.8  7.0  6.2 
* CR Crude rate per 100,000 per year 
** ASR Age standardised rate per 100,000 per yea. ASR Derived by the direct method using the  
‘World Population’. 
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stomach and liver, and lower rates for cancers of 
pancreas, skin and prostate. The high incidence of 
colorectal cancers, which is approaching that of the West 
for both males and females, is due to an increasingly 
affluent society, with lifestyle habits such as smoking 
and diets rich in meat and fat being major contributing 
factors. 
Prostate cancer is the 3
rd most common cancer in 
Singaporean males from 2001-2005, and is the number 
six cause of mortality amongst Singaporean males. The 
incidence of prostate cancer in Singaporean males is 
increasing, in part due to the widespread use of PSA 
(prostate specific antigen) as a screening test. PSA 
screening is commonly included in many health 
screening programmes.  
Breast cancer is the leading cause of death in 
Singaporean women. Singapore has one of the highest 
age-adjusted breast cancer incidences in Asia with 
increasing incidence in women in their 50’s. 
Mammographic screening in Singaporean women 
increases the rate of detection of early breast cancers, 
with acceptable recall, needle biopsy rates.  
Among the ethnic groups, colorectal, lung and 
prostate cancers were the three most common cancers 
among the three ethnic groups. Age standardised rates 
were highest among Chinese males, followed by Malay 
and Indian males.  
For females, breast and colorectal cancers were the 
most common and second most common cancers 
respectively. The age standardised rates were highest 
among Chinese females, followed by Malay and Indian 
females. Lung cancer was the third most common among 
Chinese females, fourth among Malay females and 
eighth among Indian females. 
CURRENT MANAGEMENT OF THE TOP 3 CANCERS IN 
MALES AND FEMALES 
The 3 top cancers among males and females are 
lung, colorectal and breast cancer (in females). 
Management entails surgery, radiotherapy or 
chemotherapy, either alone or in combination. 
Lung cancer 
Upon suspicion of lung cancer, definitive biopsy is 
obtained by the diagnostic radiologist or respiratory 
physician via 
1.  Fine needle aspiration and cytology 
2.  Brochoscopy and biopsy 
The patient is staged with a CT scan of the 
brain/thorax/abdomen and bone scan while a PET CT 
can be performed as an additional staging procedure, 
especially prior to surgery, to aid treatment decisions for 
selected patients. Tumour stage is ascribed following the 
2002 AJCC staging guidelines [2]. Management is 
different for non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC). 
For patients with NSCLC, surgery offers the patient 
with resectable disease the best chance of a cure. 
Surgical approaches include wedge resection, lobectomy 
or pneumonectomy. The type and extent of surgery 
performed depends on the patient’s functional status and 
extent of disease. 
Chemotherapy  is given concurrently with 
radiotherapy for patients with locally advanced disease. 
The agents used include cisplatin and vinblastine.  
In the adjuvant setting, chemotherapy is given for 
patients with Stage Ib-III disease post-resection. The 
agents used include cisplatin, vinorelbine, carboplatin 
and paclitaxel. 
Radiotherapy is an alternative for patients who are 
not suitable for surgery or for patients who decline 
surgery. Definitive radiotherapy is given for patients 
suitable for curative treatment, but decline surgery or 
chemotherapy. The dose and fractionation regimen 
depends on patient’s performance status / choice and 
treatment volume. Options include 60-70 Gy in 30-35 
fractions given over 6 to 7 weeks, or 50 Gy in 20 
fractions given over 4 weeks. Radiotherapy is delivered 
via 3-Dimensional Conformal radiotherapy (3DCRT). 
Patients with stage IIIA disease are treated with 
Surgery and/or chemoradiotherapy depending on 
performance status and patients with stage IIIB disease 
are treated with chemoradiotherapy. 
For patients who are not suitable for curative 
treatment or for patients with metastatic disease, 
palliative radiotherapy/chemotherapy or best supportive 
care are acceptable options. The aim is palliation of 
symptoms and/or prolongation of life. 
Radiotherapy techniques such as Intensity 
Modulated Radiotherapy (IMRT) are available in 
Singapore and can be used in selected cases of lung 
cancer unsuitable for surgery. Local control is important 
in NSCLC since at least 30-40% of patients die from 
local or locoregional progression of disease. For curative 
treatment, doses in the range of 60-70 Gy are required. 
IMRT allows for the improvement in therapeutic ratio. A 
recent review from the Memorial Sloan Kettering Cancer 
Centre showed that IMRT resulted in promising 
outcomes for inoperable patients with NSCLC [3].  
Currently IMRT is not the standard of care for lung 
cancer in Singapore, until technology for respiratory 
gating is available and optimised for clinical application. 
A carefully implemented respiratory gated IMRT 
programme is essential for the accurate and safe delivery 
of higher than conventional radiotherapy doses. 
Patients with limited stage SCLC are managed with 
a combination of chemotherapy and radiotherapy. 
Chemotherapy agents used include cisplatin and 
etoposide. Radiotherapy is given concurrently with 
chemotherapy, most often commencing with the 1
st or 2
nd 
cycle of chemotherapy. The dose of radiation used is in 
the order of 50-54Gy, given daily over a period of 5-6 
weeks. Radiotherapy is delivered via 3DCRT. 
Prophylactic cranial irradiation is recommended for 
suitable patients with complete and good partial response 
after chemotherapy. 
Patients with extensive stage SCLC are managed 
with palliative chemotherapy. 
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Colorectal cancer 
The diagnosis of colorectal cancer is done by 
colonoscopy and biopsy. Patients are staged with a CT 
scan of the thorax/abdomen/pelvis. A CT scan of the 
brain and bone scan is done if brain and bone metastasis 
is suspected. 
The definitive treatment for colorectal cancer is 
surgery. While surgery alone is curative for early stage 
colorectal cancer, adjuvant chemotherapy and/or 
radiotherapy is employed in patients with locally 
advanced disease to reduce the risk of local recurrence 
and improve survival. 
Surgical approaches for colon cancer includes  
1.  Polypectomy and local excisions, which is 
performed for superficial cancers or polyps.  
2.  Colectomy (hemicolectomy/segmental 
resection), which involves removing part of the 
colon as well as regional lymph nodes.  
3.  Laparoscopy-assisted colectomy, which 
involves removal of part of the colon as well as 
regional lymph nodes. 
Surgical approaches for rectal cancer includes 
1.  Polypectomy and local excisions, which is 
performed for superficial cancers or polyps 
2.  Low anterior resection, where the tumour is 
removed with the regional lymph nodes with 
preservation of anal sphincter function 
3.  Abdominal perineal resection, whereby the 
surgeon makes 2 incisions, one in the abdomen, 
another in the perineum. The tumour/regional 
lymph nodes are removed together with the 
anus and sphincter muscle. Because the anus is 
removed, a permanent colostomy is required. 
4.  Pelvic exenteration is uncommonly performed 
for locally extensive rectal cancers. A 
colostomy is required and a urostomy (opening 
on the abdominal wall for urine to flow into a 
bag) is required if the bladder is also removed. 
Adjuvant chemotherapy is given for patients with 
stage III colon cancer and also for patients with stage II 
colon cancer with high risk features (T4 disease, 
perforation of tumour, poorly differentiated tumour, 
positive margin). Agents used include 5 
Flurouracil/leucovorin with platinum based compounds 
such as oxaliplatin. Other targeted agents such as 
cetuximab are increasingly being employed. 
For colorectal cancer, adjuvant chemoradiotherapy 
is given for patients with stage T3-4 or node positive 
rectal cancer. The chemotherapy regimen used is 5 
Flurouracil/leucovorin for 5 cycles with radiotherapy 
given concurrently with the 3
rd cycle of chemotherapy.  
The dose of adjuvant radiotherapy prescribed is 45 
Gy in 25 fractions over 5 weeks duration to the whole 
pelvis, followed by a 5.4 Gy in 3 fractions to boost the 
tumour bed. This dose is increased to 9 Gy in 5 fractions 
if there is a positive margin. 
Preoperative chemoradiation can also be given for 
locally advanced rectal tumours, to attempt to down-
stage the tumour. The neoadjuvant approach has been 
shown to lead to an increase in local control, decrease 
acute toxicity and increase sphincter sparing rates. 
Adjuvant radiotherapy is not routinely given for 
colonic tumours or descending colon/sigmoid colon 
tumours above the peritoneal reflection because of 
inability to deliver radiotherapy accurately and safely to 
an organ that can move freely. Radiotherapy is delivered 
via 3DCRT. 
Breast cancer 
Breast cancer is detected using mammography, or 
by the patient either as a palpable lump, or changes in the 
breast (including nipple discharge, overlying skin 
changes). Mammographic screening enables early 
detection and intervention of breast cancers, resulting in 
a reduction in breast cancer mortality. Breast cancer is 
most commonly diagnosed by a fine needle aspiration 
and cytology. Other approaches include trucut biopsy or 
excision biopsy. 
Early breast cancer can be cured with mastectomy 
alone. With the advent of sentinel lymph node biopsy, a 
full axillary dissection can be avoided, hence avoiding 
the attendant complications of infection, seroma, 
bleeding and lymphedema. 
An alternative to mastectomy is breast conservation. 
Breast conservation therapy entails wide local excision 
with axillary surgery followed by adjuvant radiotherapy 
to the affected breast. 
The dose of adjuvant radiotherapy is 50Gy in 25 
fractions to the whole breast followed by a 10Gy in 5 
fraction boost to the tumour bed. A large number of 
randomised trials have demonstrated equivalence in long 
term survival compared with mastectomy with this 
approach. 
The use of adjuvant radiotherapy following breast 
surgery has been shown to improve the survival of 
patients in clinical studies and meta-analysis. 
Adjuvant radiotherapy is given using 3DCRT 
technique. For patients with large pendulous breast, 
IMRT can be used to reduce hot spots and to ensure a 
homogenous dose distribution, hence reducing acute and 
late side effects.  
Adjuvant hormonal therapy is prescribed if the 
patient has hormone receptive breast cancer. In 
premenopausal patients, tamoxifen (selective estrogen 
receptor antagonist) is used while in postmenopausal 
patients, tamoxifen or an aromatase inhibitor (including 
Anastrozole, Letrozole, Exemestane) can be used as an 
alternative. The aromatase inhibitors have been shown to 
have less side effects such as hot flushes, endometrial 
cancer, vaginal bleeding, cardiovascular accidents, and 
thromboembolic events compared to tamoxifen. 
However, they are associated with an increase in 
arthralgia and fractures, and hence should not be used for 
patients with osteoporosis. 
Other options of hormonal treatments include 
ovarian ablation with surgery or radiotherapy and 
ovarian function suppression with luteinising hormone-
releasing hormone agonists such as goserelin. 
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Adjuvant chemotherapy is recommended for 
patients with a combination of adverse risk factors 
including younger patients, lymph node positivity, grade 
of tumour, lymphovascular invasion, Her2neu receptor 
positivity and tumour size. 
Commonly used chemotherapy agents include 
anthracyclines such as doxorubicin in combination with 
cyclophosphamide and 5 Fluorouracil. Taxanes such as 
paclitaxel and docetaxel are used in patients with node 
positive disease, or in patients with high risk node 
negative disease. 
Locally advanced breast cancer is treated with a 
combined modality approach. Mastectomy with an 
axillary dissection is performed if the tumour is 
surgically resectable. This is followed by adjuvant 
chemotherapy and adjuvant radiotherapy respectively. 
Adjuvant hormonal treatment is recommended for 
patients with hormone responsive disease. 
Surgically unresectable tumours are treated with 
neoadjuvant chemotherapy followed by mastectomy. 
Adjuvant radiotherapy +/- hormonal therapy is given 
thereafter. 
If the tumour is still unresectable after neoadjuvant 
chemotherapy, then radiotherapy is given first before 
surgery is attempted.  
In patients who are unfit or decline chemotherapy, 
neoadjuvant hormonal therapy is an alternative to 
neoadjuvant chemotherapy in receptor-responsive 
disease. 
The dose of radiotherapy given in the adjuvant 
setting post mastectomy is 50Gy in 25# to the chest wall 
over 5 weeks duration. The supraclavicular fossa and/or 
axilla are included in the treatment fields when indicated. 
PRESENT AND FUTURE 
Since its independence in 1965, Singapore has 
quickly grown from being a developing country to a 
developed country with a population in excess of 4 
million. Cancer incidence has increased and so has 
demands for comprehensive cancer care.  
Singapore has a well-established radiotherapy 
service catering to the local as well as regional cancer 
patients. There are currently five radiotherapy centres in 
Singapore, two private centres and three centres based in 
government hospitals (which provide for both 
government subsidised and private cancer patients). For 
the public centers, the National Cancer Centre based at 
the Singapore General Hospital currently has 9 linear 
accelerators, one with Novarlis stereotactic 
radiosurgery/radiotherapy capabilities and one 
brachytherapy suite. The Cancer institute at National 
University Hospital and at Tan Tock Seng is equipped 
with 4 linear accelerators in total and one brachytherapy 
suite. In the private sector, the Gleneagles radiation 
oncology unit is equipped with two linear accelerators, 
and Mt Elizabeth Hospital with one linear accelerator 
and one state-of-the-art tomotherapy machine. Both 
private and public centres have established surgical and 
medical oncology centers to provide comprehensive 
cancer services. 
The majority of local patients are treated at public 
centres. The waiting time for radiotherapy varies from a 
few days to as long as six weeks depending on center and 
urgency of treatment. In view of the aging population 
and the rising expectations of increasingly affluent 
cancer patients seeking advanced care, there are plans for 
growth of the cancer services in both public and private 
sectors. For example, a second national cancer centre 
with enhanced radiotherapy facilities is being built at the 
Kent Ridge National University Hospital campus in 
addition to the development of at least 2-3 new private 
radiotherapy centres. All of the proposed expansion 
plans are timed to occur in the next 4-5 years. However 
the expansion will also require a significant increase in 
staff, which will not be able to be completely covered 
locally. Thus recruitment for trained, experienced staff 
will also have to be conducted regionally. In conjunction 
with the increased services there will also be more 
emphasis placed on academic development and research 
particularly in the newly planned National University 
Cancer Institute Singapore (NCIS), as mentioned above.  
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